Skip to content

Oxycodone Versus Sufentanil in Patient-controlled Intravenous Analgesia After Laparoscopic Hysterectomy

The Efficacy and Safety of Oxycodone in Patient-controlled Intravenous Analgesia After Laparoscopic Hysterectomy

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06690307
Acronym
Oxycodone
Enrollment
64
Registered
2024-11-15
Start date
2024-12-03
Completion date
2026-07-31
Last updated
2024-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laparoscopic Hysterectomy

Keywords

oxycodone, patient-controlled intravenous analgesia, laparoscopic hysterectomy

Brief summary

This study is designed to evaluate the efficacy and safety of hydrocodone in patient-controlled intravenous analgesia (PCIA) during gynecological laparoscopy, thus to explore suitable PCIA scheme to optimize postoperative pain management for patients undergoing gynecological laparoscopic surgeries.

Detailed description

The controlled group will receive sulfentanil for PCIA, and the test group will receive hydrocodone for PCIA. NRS scores at 1, 6, 24 and 48 hours post-surgery will be recorded. The usage of rescue analgesics and adverse events will also be recorded.

Interventions

Patients will receive sulfentanil for PCIA.

Sponsors

Affiliated Hospital of Nantong University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* selective laparoscopic hysterectomy * general anesthesia * ASA classification I - III * aged 18 - 65 years

Exclusion criteria

* allergy to oxycodone or any other drugs will be used in the study * preoperative opioids medication * opioids abuse * hepatic or renal dysfunction * cardiovascular or pulmonary dysfunction * lack of full civil capacity or refuse to participate

Design outcomes

Primary

MeasureTime frameDescription
NRS scores6 hours after surgeryPostoperative pain will be evaluated on a 11point number rating scale (NRS): 0 means no pain; and 10 means worst pain imaginable.

Secondary

MeasureTime frameDescription
NRS scores1, 24, 48 hours after surgeryPostoperative pain will be evaluated on a 11point number rating scale (NRS): 0 means no pain; and 10 means worst pain imaginable.
rescue analgesics usagefrom the end of surgery to the first usage (up to 48 hours post-surgery)time to the first use of rescue analgesics
PCIA pressing times48 hours after surgerytotal pressing times and effective pressing times
anal exhaust timefrom the end of surgery to the first anal exhaust (up to 48 hours post-surgery)
adverse eventswithin 48 hours after surgerydizziness, drowsiness, nausea and vomiting, intestinal paralysis, skin itching, respiratory depression, intestinal obstruction, severe allergic reactions, and serious cardiovascular adverse events

Countries

China

Contacts

Primary ContactSiyuan Liu, PhD
tdfylsy@ntu.edu.cn+86-85050301

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026